A London cell therapy company building engineered regulatory T cell (Treg) treatments for liver transplant and autoimmune conditions.
Quell Therapeutics develops cell therapies that use regulatory T cells, a type of immune cell that calms the immune system. Its lead treatment, QEL-001, aims to help liver transplant patients avoid taking strong drugs for life to stop rejection.
The company says it aims to "harness, direct and optimize" the immune-calming properties of these cells, and to deliver "truly innovative, life-changing therapies for our patients" (company's own words, from a 2021 release and a job page).
Quell is based in London at the Translation and Innovation Hub at Wood Lane (White City), and makes clinical-trial supplies at the Cell and Gene Therapy Catapult site in Stevenage, Hertfordshire (as at 2021, extended through that collaboration).
A careers-site profile lists 101 to 200 employees, flexible working, 25 days' holiday and a pension. It shows a Glassdoor rating of 2.8, so it is worth reading reviews and asking about culture at interview. These details are third-party and undated.
We found no open roles listed at the time we looked, and no graduate scheme, internship or apprenticeship information. Check Quell's careers page and the Cell and Gene Therapy Catapult for science and manufacturing routes into the sector.
Website: www.quell-tx.com
PURPOSE helps school and university students explore 62 sectors and over 1,000 entry-level careers in the UK, then connects them directly with employers.
Explore PURPOSE